Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Chronic Myelogenous Leukemia
  • Acquired Bone Marrow Failure Syndromes
  • Marginal Zone B Cell Lymphoma
  • Prolymphocytic Leukemia
  • Acute Leukemia
  • Acute Lymphoblastic Leukemia
  • Plasma Cell Leukemia
  • Multiple Myeloma
  • Acute Myeloid Leukemia
  • Myelodysplasia
  • Mantle Cell Lymphoma
  • Natural Killer Cell Malignancies
  • Biphenotypic/Undifferentiated/Prolymphocytic Leukemias
  • Burkitt Lymphoma
  • Chronic Lymphocytic Leukemia
  • High Risk Anemia
  • Refractory Anemia
  • Lymphoplasmacytic Lymphoma
  • Diffuse Large Cell Non Hodgkins Lymphoma
  • Myeloproliferative Neoplasms
  • Follicular Lymphoma
  • Lymphoma
  • Small Lymphocytic Lymphoma
  • Myelofibrosis
  • Juvenile Myelomonocytic Leukemia
  • Lymphoblastic Lymphoma
  • High Grade Non-Hodgkin's Lymphoma, Adult
  • MRD Positive Leukemia
Type
Interventional
Phase
Phase 2
Design
Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Younger than 60 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT03314974
Collaborators
Not Provided
Investigators
Principal Investigator: Shernan Holtan, MD Masonic Cancer Center, University of Minnesota